Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer.

Trial Profile

Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BOXER
  • Most Recent Events

    • 01 Aug 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database record.
    • 24 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top